Madrigal Pharmaceuticals (MDGL) Assets Average (2011 - 2026)

Madrigal Pharmaceuticals (MDGL) has 16 years of Assets Average data on file, last reported at $1.2 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $1.2 billion, up 21.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 21.97% YoY), and the FY2025 annual result was $1.2 billion, up 36.79% from the prior year.
• Assets Average fell to $1.2 billion in Q1 2026 per MDGL's latest filing, from $1.3 billion in the prior quarter.
• Over five years, Assets Average peaked at $1.3 billion in Q4 2025 and troughed at $187.5 million in Q3 2022.
• A 5-year average of $715.0 million and a median of $861.4 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2024: Assets Average slumped 40.72% in 2022, then surged 302.1% in 2024.
• A 5-year view of Assets Average shows it stood at $260.6 million in 2022, then soared by 68.55% to $439.3 million in 2023, then soared by 140.81% to $1.1 billion in 2024, then advanced by 23.94% to $1.3 billion in 2025, then slipped by 5.15% to $1.2 billion in 2026.
• Business Quant data shows MDGL's Assets Average at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.